Ilan Zipkin

Mr Ilan Zipkin


Ilan is a Partner of Prospect Venture Partners. He joined the firm in 2005, and is focused on investments in biotechnology companies, primarily therapeutics but also including platform technologies. In addition to his investment activities, Ilan is currently serving as the CEO of Chimeros, Inc., a Prospect portfolio company developing a protein-based system for the delivery of siRNA therapeutics as well as other oligonucleotides and biologics. Ilan also serves on the Board of Directors of Alvine Pharmaceuticals, Chimeros, and Satori Pharmaceuticals. Prior to joining Prospect Venture Partners, Ilan was a Principal at MPM Capital, and had been promoted to General Partner for MPM's next fund. At MPM, Ilan was involved with investments in biotechnology and specialty pharmaceutical companies including Somaxon Pharmaceuticals (NASDAQ:SOMX), Neuromed Pharmaceuticals (now Zalicus Inc., NASDAQ:ZLCS), Pharmasset (NASDAQ: VRUS), KaloBios, Rinat Neuroscience (NYSE: PFE, acquired) and ARYx Therapeutics (NASDAQ: ARYX). Ilan also worked with MPM Capital's BioEquities hedge fund, which invested in small- to mid-cap public biotechnology companies. Prior to joining MPM Capital in 2000, Ilan was the Science Editor of BioCentury Publications Inc., a biotechnology news and analysis publication.
Ilan received a Ph.D. in cell biology and biochemistry from the University of California at San Francisco (UCSF), and a B.A. in Molecular and Cell Biology from U.C. Berkeley.


Venture capital firm
Partner (Palo Alto) (current)

Add education